Dehydroabietylamine exerts antitumor effects by affecting nucleotide metabolism in gastric cancer

Jingsong Ma,Jiabao Zhao,Zhengxin Wu,Jinshui Tan,Meijuan Xu,Wenjie Ye,Mengya Zhong,Yubo Xiong,Guangchao Pan,Huiwen Zhou,Shengyi Zhou,Xuehui Hong

DOI: https://doi.org/10.1093/carcin/bgae037

2024-06-15

Carcinogenesis

Abstract:Nucleotide metabolism is the ultimate and most critical link in the self-replication process of tumors, including gastric cancer (GC). However, in clinical treatment, classic anti-tumor drugs such as 5-fluorouracil (5-FU) are mostly metabolic analogues of purines or pyrimidines, which lack specificity for tumor cells and therefore have significant side effects. It is unclear whether there are other drugs that can target nucleotide metabolism, except for nucleic acid analogues. Here, we found that a natural compound, dehydroabietylamine (DHAA), significantly reduced the viability and proliferation of GC cells and organoids. DHAA disrupts purine and pyrimidine metabolism of GC cells, causing DNA damage and further inducing apoptosis. DHAA treatment decreased transcription and protein levels of key enzymes involved in nucleotide metabolism pathway, with significant reductions in the expression of pyrimidine metabolism key enzymes CAD, DHODH, and purine metabolism key enzymes PAICS. We also found that DHAA directly binds to and reduces the expression of Forkhead box K2 (FOXK2), a common transcription factor for these metabolic enzymes. Ultimately, DHAA was shown to delay tumorigenesis in K19-Wnt1/C2mE transgenic mice model and reduce levels of CAD, DHODH, and PAICS in vivo. We demonstrate that DHAA exerts an anticancer effect on GC by targeting transcription factor FOXK2, reducing transcription of key genes for nucleotide metabolism and impairing nucleotide biosynthesis, thus DHAA is a promising candidate for GC therapy.

oncology

What problem does this paper attempt to address?

This paper primarily discusses the anti-tumor effects of dehydroabietylamine (DHAA) on gastric cancer (GC), with a focus on how DHAA affects nucleotide metabolism. The study found that DHAA significantly reduces the viability and proliferation of gastric cancer cells and organoids. By interfering with purine and pyrimidine metabolism, DHAA causes DNA damage and further induces apoptosis. Specifically, DHAA decreases the transcription and protein levels of key enzymes involved in nucleotide metabolism pathways, such as CAD, DHODH, and PAICS, and directly binds to the transcription factor FOXK2, reducing its expression. FOXK2 is a common transcription factor for these metabolic enzymes.

Moreover, experiments in the K19-Wnt1/C2mE transgenic mouse model confirmed that DHAA can delay tumor development and reduce the expression of key enzymes CAD, DHODH, and PAICS in vivo. In summary, DHAA exhibits potential for gastric cancer treatment by targeting FOXK2, inhibiting the transcription of nucleotide metabolism genes, and thereby hindering nucleotide biosynthesis.